Ozempic vs Contrave: Complete Mechanism & Weight Loss Comparison

Ozempic injection and Contrave have different indications, mechanisms, trial evidence and risks. Separate obesity trials are not a direct comparison, and Contrave is not a depression treatment or universally safer oral alternative.

Mechanism of Action: How They Work Differently

Compare the actual product and indication before comparing mechanisms. A receptor-pathway explanation does not establish faster loss, a universal winner or suitability for a particular patient.

Ozempic (Semaglutide): Direct Appetite Suppression

Semaglutide activates GLP-1 receptors and can improve glucose regulation and reduce appetite; it delays gastric emptying. These actions do not guarantee a fixed intake reduction, weight-loss amount or symptom timetable. Ozempic injection, Ozempic tablets, Wegovy and Rybelsus have product-specific instructions.

The current Ozempic injection label covers adult type 2 diabetes, cardiovascular-risk reduction in adults with type 2 diabetes and established cardiovascular disease, and a kidney/CV composite indication in adults with type 2 diabetes and chronic kidney disease. It is not an obesity indication. Ozempic tablets also now have a separate oral label; daily tablet and weekly injection milligrams are not interchangeable.

Contrave (Naltrexone/Bupropion): Multi-Target Approach

Contrave combines extended-release naltrexone, an opioid antagonist, with bupropion, a norepinephrine/dopamine reuptake inhibitor. It is approved for long-term weight management in eligible adults with obesity or overweight plus a weight-related condition. Its appetite-pathway rationale does not establish a predictable mood, energy or onset benefit, and it is not approved to treat depression.

Weight Loss Efficacy: Side-by-Side Comparison

COR-I randomized 1,742 adults to naltrexone/bupropion or placebo for 56 weeks. The published primary modified analysis, using on-treatment observations and last observation carried forward, reported 6.1% mean loss with 32/360 mg daily versus 1.3% with placebo; only half completed 56 weeks. The current label’s broader ITT account reports 5.4% versus 1.3%. These favorable but analysis-dependent results are not a direct comparison with semaglutide. The trial was funded by Orexigen.

STEP 1 randomized 1,961 adults without diabetes to weekly semaglutide 2.4 mg or placebo with lifestyle support for 68 weeks. Treatment-policy mean loss was 14.9% versus 2.4%. This favorable Novo Nordisk-funded obesity result is not an Ozempic 1-mg trial or a personal forecast.

STEP 1 used semaglutide 2.4 mg, not Ozempic 1 mg. COR-I differs in population, follow-up, missing-data methods and completion. Subtracting these trial means does not produce a head-to-head effect.

Side Effects Comparison

Contrave has a boxed warning about suicidal thoughts/behaviors associated with antidepressants and requires attention to mood changes. Contraindications include uncontrolled hypertension, seizures, anorexia/bulimia, other bupropion products, chronic opioid use or acute withdrawal, abrupt withdrawal of certain sedatives/alcohol, recent MAO inhibitors and relevant allergy. It can increase BP/heart rate and affect opioid pain treatment; kidney/liver impairment changes instructions. Pregnancy requires stopping weight-loss treatment and contacting the prescriber. It is not automatically safe because someone is not depressed.

Both medicines can cause nausea or other GI symptoms, while their other adverse effects and precautions differ. Separate-study percentages cannot rank severity or establish that symptoms will resolve on a fixed schedule.

Semaglutide labels have a boxed rodent thyroid C-cell tumor warning; human relevance is unknown. Personal/family medullary thyroid carcinoma or MEN 2, and serious hypersensitivity to the respective product, are formal contraindications. Pancreatitis, gallbladder disease, dehydration-related kidney injury, severe GI effects and aspiration around anesthesia require attention; hypoglycemia risk increases with insulin or sulfonylureas. A rare-event percentage from one study cannot quantify every person’s risk.

Dosing and Administration

Use the actual product label and prescription rather than a shared dosing ladder.

For weekly Ozempic injection, the label starts at 0.25 mg for four weeks, then 0.5 mg; increases to 1 mg and then 2 mg require at least four weeks at the preceding dose when additional glycemic control is needed. The 0.25-mg dose is for initiation. Ozempic does not have labeled 1.5-, 1.7- or 2.4-mg injection steps; the CKD outcome indication has a specified 1-mg maintenance instruction.

Each Contrave tablet contains 8 mg naltrexone/90 mg bupropion. Its label starts with one morning tablet, increasing over four weeks to two tablets in the morning and two in the evening—not four daily dosing times. Avoid high-fat meals and follow product-specific precautions. Reassess after 12 weeks at maintenance: the label calls for stopping if loss is below 5% of baseline. This stopping rule is not a general Ozempic rule.

Cost Comparison

Original Contrave $250–$400 and Ozempic $890–$1,200 monthly retail figures were historical examples, not current quotes or guaranteed comparative savings. Copays and eligibility vary; confirm product, pharmacy, fees and plan terms. For broader online weight-management care, SurpassMD describes its program and assessment process.

Who Should Use Ozempic vs Contrave?

Choose around the actual treatment goal, approved indication, prior response, risks, available formulations and sustainable access. More average weight loss does not necessarily mean the best option for an individual. Type 2 diabetes, established cardiovascular disease, CKD, obesity or OSA can change which product-specific evidence matters. An arbitrary three-month percentage threshold or cost-first ladder does not settle every decision.

Choose Ozempic If You:

Ozempic injection may fit its type 2 diabetes/CV/CKD indication in an appropriate patient. Those benefits are not a blanket recommendation for anyone with heart or kidney disease or a substitute for an approved obesity-product assessment.

Choose Contrave If You:

Contrave combines extended-release naltrexone, an opioid antagonist, with bupropion, a norepinephrine/dopamine reuptake inhibitor. It is approved for long-term weight management in eligible adults with obesity or overweight plus a weight-related condition. Its appetite-pathway rationale does not establish a predictable mood, energy or onset benefit, and it is not approved to treat depression.

An oral option can matter, but Contrave is not a mood/energy prescription or a universally milder GLP-1 alternative. Current oral weight-management options also exist; the decision is not simply pill versus weekly injection.

Medical Considerations & Contraindications

Contrave has a boxed warning about suicidal thoughts/behaviors associated with antidepressants and requires attention to mood changes. Contraindications include uncontrolled hypertension, seizures, anorexia/bulimia, other bupropion products, chronic opioid use or acute withdrawal, abrupt withdrawal of certain sedatives/alcohol, recent MAO inhibitors and relevant allergy. It can increase BP/heart rate and affect opioid pain treatment; kidney/liver impairment changes instructions. Pregnancy requires stopping weight-loss treatment and contacting the prescriber. It is not automatically safe because someone is not depressed.

Semaglutide labels have a boxed rodent thyroid C-cell tumor warning; human relevance is unknown. Personal/family medullary thyroid carcinoma or MEN 2, and serious hypersensitivity to the respective product, are formal contraindications. Pancreatitis, gallbladder disease, dehydration-related kidney injury, severe GI effects and aspiration around anesthesia require attention; hypoglycemia risk increases with insulin or sulfonylureas. A rare-event percentage from one study cannot quantify every person’s risk.

Severe or persistent abdominal pain, repeated vomiting with inability to retain fluids, marked dehydration or a serious allergic reaction needs prompt assessment. Suspected pancreatitis calls for stopping the drug and evaluation; severe allergic symptoms require urgent care. Significant gastroparesis, retinopathy, pregnancy plans and other medicines affect selection. Semaglutide labels advise stopping at least two months before a planned pregnancy.

Can You Use Both Ozempic and Contrave?

The assessed evidence does not establish a routine Contrave–semaglutide combination benefit or safety. Neither an assumed stronger monotherapy nor a mechanistic argument settles the question. The exact medicines, opioid needs, psychiatric history and interactions require review.

Long-Term Use & Weight Regain

STEP 4 randomized selected adults after a 20-week semaglutide run-in: over the subsequent 48 weeks, continuing treatment produced further loss while switching to placebo led to regain. SURMOUNT-4 similarly found maintenance/further loss with continued tirzepatide and regain after withdrawal following its run-in. These selected randomized-withdrawal results support ongoing management, but do not mean everyone regains the same amount or that lifestyle cannot help.

Regain can follow withdrawal, but no study here establishes that every person regains all weight in three to six months after either medicine. Continuation and stopping should account for response, risks and follow-up.

Primary references: Ozempic injection label, Wegovy label, Contrave label.

Related Guides